Sector News

Lilly appoints Philip Johnson to Senior Vice President and Treasurer

November 14, 2017
Life sciences

Eli Lilly and Company has announced Philip Johnson has been appointed to senior vice president, Finance, and treasurer effective January 1, 2018.

Johnson currently serves as vice president for Investor Relations at Lilly. He will report to Joshua Smiley, who will become senior vice president and chief financial officer effective January 1, 2018. Johnson will continue to lead Lilly’s investor relations efforts.

“Phil has been a trusted partner for our shareholders, effectively communicating the company’s results and expectations, while ensuring management’s actions are informed by shareholder input,” Smiley said. “With his external focus and experience in the capital markets, Phil is an ideal candidate to assume this important position and to help guide Lilly’s financial strategy.”

Johnson has been with Lilly 22 years, serving in a variety of financial roles in the U.S. and overseas. He has been in his current role since 2007 and before that was vice president, Finance, and chief financial officer for Global Manufacturing and Quality. Prior to joining Lilly, Johnson worked for six years in investment banking and management consulting in the U.S. and Europe.

Source: Eli Lilly and Company

comments closed

Related News

December 3, 2023

FDA names chief scientist Bumpus as Woodcock’s successor

Life sciences

The Food and Drug Administration’s top scientist Namandjé Bumpus will assume the role of principal deputy commissioner when longtime agency leader Janet Woodcock retires from that role in early 2024, according to an announcement Thursday.

December 3, 2023

AbbVie to buy cancer drug maker ImmunoGen for $10.1 Billion

Life sciences

US biopharma AbbVie has agreed to acquire ImmunoGen in a deal which values the company at about $10.1 billion and gives AbbVie access to flagship cancer therapy Elahere (mirvetuximab soravtansine-gynx), a first-in-class antibody-drug conjugate (ADC) approved for platinum-resistant ovarian cancer (PROC), as well as a pipeline of promising next-generation ADCs.

December 3, 2023

EuroAPI appoints new Executive Committee members

Life sciences

EUROAPI today announced the appointment of David Seignolle as Chief Operating Officer, succeeding Eric Berger, and Marion Santin as Chief Legal, Compliance, and IP Officer, both joining the company’s Executive Committee. In his new role, David Seignolle will lead the transformation of the Industrial Operations organization.

How can we help you?

We're easy to reach